Are prostate-specific antigen changes valid surrogates for survival in hormone-refractory prostate cancer? A meta-analysis is needed! - In reply

被引：0
|
作者：
Armstrong, Andrew J. [1 ]
Garrett-Mayer, Elizabeth [2 ]
Eisenberger, Mario [2 ]
Tannock, Ian [3 ,4 ]
de Wit, Ronald [5 ]
机构：
[1] Duke Comprehens Canc Ctr, Durham, NC 27710 USA
[2] Johns Hopkins Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[3] Princess Margaret Hosp, Dept Med Oncol, Toronto, ON M4X 1K9, Canada
[4] Univ Toronto, Toronto, ON, Canada
[5] Erasmus Univ, Med Ctr, Rotterdam Canc Inst, Dept Med Oncol, Rotterdam, Netherlands
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 35期
关键词：
D O I：
10.1200/JCO.2007.14.5383
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：5674 / 5674
页数：1
相关论文
共 50 条
  • [1] Are prostate-specific antigen changes valid surrogates for survival in hormone-refractory prostate cancer? A meta-analysis is needed!
    Collette, Laurence
    Buyse, Marc
    Burzykowski, Tomasz
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (35) : 5673 - 5674
  • [2] Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer
    Semeniuk, Ross C.
    Venner, Peter M.
    North, Scott
    UROLOGY, 2006, 68 (03) : 565 - 569
  • [3] Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer
    Armstrong, Andrew J.
    Garrett-Mayer, Elizabeth
    Yang, Yi-Chun Ou
    Carducci, Michael A.
    Tannock, Ian
    de Wit, Ronald
    Eisenberger, Mario
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (25) : 3965 - 3970
  • [4] Analysis of prostate-specific antigen decline as a surrogate for overall survival in metastatic hormone-refractory prostate cancer (HRPC)
    Armstrong, A. J.
    Eisenberger, M. A.
    Garrett-Mayer, E. S.
    Yang, Y. Ou
    Carducci, M. A.
    de Wit, R.
    Tannock, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [5] Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer
    Sartor, O
    Weinberger, M
    Moore, A
    Li, AL
    Figg, WD
    UROLOGY, 1998, 52 (02) : 252 - 256
  • [6] Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinoma
    Rozhansky, F
    Chen, MH
    Cox, MC
    Dahut, W
    Figg, WD
    D'Amico, AV
    CANCER, 2006, 106 (01) : 63 - 67
  • [7] Survival analyses overview in hormone-refractory prostate cancer clinical trials in the prostate-specific antigen era
    Sartor, Oliver
    CLINICAL GENITOURINARY CANCER, 2007, 5 (07) : 420 - 421
  • [8] Prostate-specific antigen doubling time: A potential surrogate end point in hormone-refractory prostate cancer - Reply
    Dawson, NA
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (05) : 1646 - 1646
  • [9] PROSTATE-SPECIFIC ANTIGEN AS A MEASURE OF DISEASE OUTCOME IN METASTATIC HORMONE-REFRACTORY PROSTATE-CANCER
    KELLY, WK
    SCHER, HI
    MAZUMDAR, M
    VLAMIS, V
    SCHWARTZ, M
    FOSSA, SD
    JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (04) : 607 - 615
  • [10] Prostate-specific antigen response to withdrawal of megestrol acetate in a patient with hormone-refractory prostate cancer
    Wehbe, TW
    Stein, BS
    Akerley, WL
    MAYO CLINIC PROCEEDINGS, 1997, 72 (10) : 932 - 934
12345